^
    Back
    Association details:
    Biomarker:MSLN positive
    Cancer:Mesothelioma
    Drug:gavocabtagene autoleucel (TC-210) (T-cell stimulant, Mesothelin inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

    Excerpt:
    ...For Serous Ovarian Adenocarcinoma, patients must have confirmed positive MSLN expression on >/= 30% of tumor cells that are 1+, 2+, and/or 3+ by immunohistochemistry (IHC)....
    Trial ID:
    NCT03907852
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    SITC 2021
    Title:

    173 Expression of a membrane-tethered IL-15/IL-15 receptor fusion protein enhances the persistence of MSLN-targeted TRuC-T cells FREE

    Published date:
    11/09/2021
    Excerpt:
    ...MHC class I/II deficient NSG mice bearing human mesothelioma xenografts...These pre-clinical studies suggest that the IL-15fu can synergize with TC-210 to increase the potency and durability of response in patients with MSLN+ tumors.
    DOI:
    http://dx.doi.org/10.1136/jitc-2021-SITC2021.173